Chimeric Antigen Receptor T-cell Therapy for Cancer: A Basic Research-Oriented Perspective

Abstract

Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma's investment in the field of T-cell therapeutics. This interest has led to the discovery of key factors that affect CAR T-cell efficacy and play pivotal roles in T-cell immunology. Herein, we introduce advances in adoptive immunotherapy and the birth of CAR T cells, and review CAR T-cell studies that focus on three important features: CAR constructs, target antigens and T-cell phenotypes. At last, we highlight novel strategies that overcome the tumor microenvironment and circumvent CAR T-cell side effects, and consider the future direction of CAR T-cell development.

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

“…Similarly, IL-13 overexpression was found involved in the immunosuppression. Binding of IL-13Rα1/IL-4Rα and IL-13 results in apoptosis escape in glioblastoma cells usually induced by signal transducer and STAT-6 pathways is considered another significant hypothesis in this case (Han & Kwon, 2018 ). Conclusively, it is derived that removal of IL-13 from the system would be a factor toward escape of apoptosis from glioblastoma cells.…”